Advertisement
Entropy Neurodynamics Limited

Entropy Neurodynamics Limited Fundamental Analysis

ENP.AXASX
HealthcareBiotechnology
$0.03
$0.00(0.00%)
Australian Market opens in 48h 59m
Advertisement

Entropy Neurodynamics Limited Fundamental Analysis

Entropy Neurodynamics Limited (ENP.AX) shows weak financial fundamentals with a PE ratio of -13.91, profit margin of 0.00%, and ROE of -68.12%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position13.38%
PEG Ratio-0.14
Current Ratio7.78

Areas of Concern

ROE-68.12%
Operating Margin0.00%
We analyze ENP.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -48.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-48.7/100

We analyze ENP.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

ENP.AX struggles to generate sufficient returns from assets.

ROA > 10%
-52.21%

Valuation Score

Excellent

ENP.AX trades at attractive valuation levels.

PE < 25
-13.91
PEG Ratio < 2
-0.14

Growth Score

Weak

ENP.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

ENP.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
7.78

Profitability Score

Weak

ENP.AX struggles to sustain strong margins.

ROE > 15%
-6811.97%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ENP.AX Expensive or Cheap?

P/E Ratio

ENP.AX trades at -13.91 times earnings. This suggests potential undervaluation.

-13.91

PEG Ratio

When adjusting for growth, ENP.AX's PEG of -0.14 indicates potential undervaluation.

-0.14

Price to Book

The market values Entropy Neurodynamics Limited at 6.04 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.04

EV/EBITDA

Enterprise value stands at -9.20 times EBITDA. This is generally considered low.

-9.20

How Well Does ENP.AX Make Money?

Net Profit Margin

For every $100 in sales, Entropy Neurodynamics Limited keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-68.12 in profit for every $100 of shareholder equity.

-68.12%

ROA

Entropy Neurodynamics Limited generates $-52.21 in profit for every $100 in assets, demonstrating efficient asset deployment.

-52.21%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

ENP.AX converts -10.24% of its market value into free cash.

-10.24%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.91

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.14

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.04

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.78

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.68

vs 25 benchmark

ROA

Return on assets percentage

-0.52

vs 25 benchmark

ROCE

Return on capital employed

-0.78

vs 25 benchmark

How ENP.AX Stacks Against Its Sector Peers

MetricENP.AX ValueSector AveragePerformance
P/E Ratio-13.9130.23 Better (Cheaper)
ROE-68.12%403.00% Weak
Net Margin0.00%-11442.00% (disorted) Weak
Debt/Equity0.080.78 Strong (Low Leverage)
Current Ratio7.784.98 Strong Liquidity
ROA-52.21%-248.00% (disorted) Weak

ENP.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Entropy Neurodynamics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ